World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 23 April 2019
Main ID:  NCT00310180
Date of registration: 29/03/2006
Prospective Registration: Yes
Primary sponsor: National Cancer Institute (NCI)
Public title: Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) TAILORx
Scientific title: Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Date of first enrolment: April 7, 2006
Target sample size: 10273
Recruitment status: Active, not recruiting
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 3
Countries of recruitment
Australia Canada Ireland New Zealand Peru Puerto Rico United Kingdom United States
Name:     Joseph A Sparano
Affiliation:  ECOG-ACRIN Cancer Research Group
Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients with operable histologically confirmed adenocarcinoma of the female breast
who have completed primary surgical treatment and meet the following criteria:

- ER and/or progesterone receptor (PR)-positive: Estrogen and/or progesterone
receptor positive disease (as defined by local pathology laboratory)

- Negative axillary nodes: As assessed by a sentinel lymph node biopsy, an axillary
dissection, or both, and as defined by the Sixth Edition of the American Joint
Committee on Cancer (AJCC) staging criteria

- Tumor size 1.1-5.0 cm (or 5 mm-1.0 cm plus unfavorable histological features):

- Unfavorable features defined as intermediate or poor nuclear and/or
histologic grade, or lymphovascular invasion

- NOTE: Definition of tumor size: The tumor size used for determination of
eligibility is the pathologic tumor size, which is usually determined by the
size of the tumor as measured by inspection of the gross specimen; if the
tumor size is measured microscopically and the tumor includes ductal
carcinoma in-situ, the measurement should include only the invasive
component of the tumor

- The tumor must be human epidermal growth factor receptor 2 (Her2)/neu negative by
either fluorescent in-situ hybridization (FISH) or immunohistochemistry (e.g. 0
or 1+ by DAKO Herceptest)

- The patient and physician must be agreeable to initiate standard chemotherapy and
hormonal therapy as adjuvant therapy

- A tissue specimen from the primary breast cancer has been located and is ready to be
shipped to the appropriate laboratory after consent is obtained and within 3 days
following pre-registration; NOTE: For determination of the Oncotype Recurrence Score,
tissue must be shipped to Genomic Health; if the Oncotype DX Recurrence Score was
previously performed by Genomic Health (prior to pre-registration), tissue must be
submitted to the Eastern Cooperative Oncology Group (ECOG)-American College of
Radiology Imaging Network (ACRIN) Central Biorepository and Pathology Facility upon

- Leukocyte count >= 3500/mm^3

- Platelets >= 100,000/mm^3

- Serum creatinine =< 1.5 mg/dL

- Serum aspartate transaminase (AST) that is =< 3-fold the upper institutional limits of

- Patients must be disease-free of prior invasive malignancies for >= 5 years with the
exception of curatively-treated basal cell or squamous cell carcinoma of the skin or
carcinoma in situ of the cervix; patients with a previous ipsilateral or contralateral
invasive breast cancer, or with bilateral synchronous cancers, are not eligible;
patients with previous ipsilateral or contralateral ductal in situ carcinoma (DCIS)
are not eligible

- Prior treatment

- Mandatory prior surgery criteria:

- Patient must pre-register within 84 days from the final surgical procedure
required to adequately treat the primary tumor (please note that if margins
are not clear and a resection has to be conducted after pre-registration but
before randomization, the patient will be deemed to be within the 84 day
window allowed by protocol and therefore eligible)

- All tumors should be removed by either a mastectomy or local excision plus
an acceptable axillary procedure (i.e., sentinel lymph node biopsy, axillary
dissection, or both); there must be adequate (at least 1 mm if margin width
specified) tumor-free margins of resection (for invasive and ductal
carcinoma in-situ) in order for the patients to be eligible; patients with
lobular carcinoma in-situ involving the resection margins are eligible

- Criteria re: other prior treatments:

- No prior chemotherapy for this malignancy

- No prior radiation therapy for this malignancy; this includes no prior
MammoSite Brachytherapy radiation therapy (RT)

- Hormonal therapy: Patients who develop breast cancer while receiving a
selective estrogen-receptor modulator (SERM; e.g., tamoxifen, toremifene,
raloxifene) or an aromatase inhibitor (e.g., anastrazole, letrozole,
exemestane) for breast cancer prevention or a SERM for other indications
(e.g., raloxifene for osteoporosis) are not eligible; however, patients may
have received up to 8 weeks of a SERM or aromatase inhibitor for this
malignancy and still be eligible for study entry

- Patients must have an anticipated life expectancy of at least 10 years

- Patients with the following medical conditions should not be enrolled on the study:

- Chronic obstructive pulmonary disease requiring treatment

- Chronic liver disease (e.g., cirrhosis, chronic active hepatitis)

- Previous history of a cerebrovascular accident

- History of congestive heart failure or other cardiac disease that would represent
a contraindication to the use of an anthracycline (e.g., doxorubicin or

- Chronic psychiatric condition or other condition that would impair compliance
with the treatment regimen

- Women must not be pregnant or breast-feeding; all females of childbearing potential
must have a blood test or urine study within 2 weeks prior to pre-registration to rule
out pregnancy

- Women of childbearing potential must be strongly advised to utilize an accepted
and effective form of non-hormonal contraception (e.g. intrauterine device,
condoms, diaphragm, abstinence)

- Patients must not have previously had the Oncotype DX Assay performed, with the
exception of patients who have had the assay performed and have a recurrence score of

Age minimum: 18 Years
Age maximum: 75 Years
Gender: Female
Health Condition(s) or Problem(s) studied
Breast Adenocarcinoma
Estrogen Receptor and/or Progesterone Receptor Positive
HER2/Neu Negative
Stage IA Breast Cancer AJCC v7
Stage IB Breast Cancer AJCC v7
Stage IIA Breast Cancer AJCC v6 and v7
Stage IIB Breast Cancer AJCC v6 and v7
Stage IIIB Breast Cancer AJCC v7
Drug: Anastrozole
Drug: Exemestane
Drug: Letrozole
Drug: Tamoxifen Citrate
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
Primary Outcome(s)
5-year Disease-free Survival [Time Frame: Assessed every 6 months within 5 years from registration and then annually up to 20 years, DFS rate estimated at 5 years]
Secondary Outcome(s)
5-year Disease-free Survival by Age and Recurrence Score Groups [Time Frame: Assessed every 6 months within 5 years from registration and then annually up to 20 years, DFS rate estimated at 5 years]
5-year Disease-free Survival by Individual RS Gene Groups [Time Frame: Assessed every 6 months within 5 years from registration and then annually up to 20 years]
5-year Distant Recurrence-free Interval [Time Frame: Assessed every 6 months within 5 years from registration and then annually up to 20 years, DRFI rate estimated at 5 years]
5-year Overall Survival [Time Frame: Assessed every 6 months within 5 years from registration and then annually up to 20 years, OS rate estimated at 5 years]
5-year Recurrence-free Interval [Time Frame: Assessed every 6 months within 5 years from registration and then annually up to 20 years, RFS rate estimated at 5 years]
To Compare the Outcomes Projected at 10 Years by Adjuvant! With Those Made by the Genomic Health Oncotype DX Test [Time Frame: Assessed at 10 years after study entry]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
American College of Surgeons
Cancer and Leukemia Group B
NCIC Clinical Trials Group
North Central Cancer Treatment Group
NSABP Foundation Inc
Southwest Oncology Group
Ethics review
Results available: Yes
Date Posted: 12/03/2019
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history